Intellia's Crispr-Based Therapy Meets Goals in Phase 3 Hereditary Angioedema Trial

Intellia's Crispr-Based Therapy Meets Goals in Phase 3 Hereditary Angioedema Trial
2 min readHealthScienceTechnology

In Brief

The trial's success marks a significant milestone for in vivo gene editing, potentially advancing treatment options for hereditary angioedema.

Key Facts

  • Intellia Therapeutics reported its Crispr-based treatment met primary goals in a Phase 3 trial for hereditary angioedema.
  • The company has initiated a rolling submission of a Biologics License Application to the FDA for Lonvoguran Ziclumeran (lonvo-z) as a one-time treatment.
  • The therapy is designed to reduce swelling episodes associated with hereditary angioedema.
  • This is described as a global first for in vivo gene editing in a pivotal clinical trial.
  • Intellia Therapeutics announced the results and regulatory plans within the past three hours.

What Happened

Intellia Therapeutics announced that its Crispr-based therapy for hereditary angioedema achieved its objectives in a Phase 3 clinical trial, and the company has begun submitting data to the FDA for approval.

Why It Matters

The results represent a major development in gene editing, as this is reported to be the first successful pivotal trial of an in vivo Crispr therapy. If approved, it could offer a new one-time treatment option for patients with hereditary angioedema.

What's Next

Regulatory review by the FDA is underway following Intellia's rolling submission. Further updates on approval status and potential commercialization are expected.

Sources